Uniqure Stock Rises Pre-Market After Investigational Huntington's Disease Drug Slows Disease In Trial

2025-09-24 10:12:10

(MENAFN- AsiaNet News)

uniQure N.V. (QURE) on Wednesday said that a high dose of its experimental drug AMT-130 demonstrated a statistically significant slowing of disease progression in Huntington's disease in an early-to-mid stage trial.

Huntington's disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, behavioral abnormalities, and cognitive decline. The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale (cUHDRS), a comprehensive assessment tool used in clinical trials for Huntington's disease.

Shares of the company rose 3% in the pre-market session at the time of writing.

Get updates to this developing story <directly on Stocktwits.

MENAFN24092025007385015968ID1110105575

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.